In this issue of Blood Advances, Blachez et al1 report findings from a nationwide French cohort of pediatric cases of autoimmune hemolytic anemia (AIHA). Their analysis, which focused on AIHA cases with an isolated C3d-positive direct antiglobulin test (DAT), affords insight into a clinical entity that remains poorly understood and offers guidance on its clinical management.
AIHA is broadly classified by the temperature of antibody reactivity and the DAT pattern; warm AIHA is usually immunoglobulin G (IgG) ± C3d-positive, and cold AIHA typically displays isolated C3d-positivity. Cold AIHA develops as a consequence of either cold-reactive immunoglobulin M autoantibodies (ie, in cold agglutinin disease [CAD], secondary cold agglutinin syndrome [CAS]), or biphasic IgG (Donath-Landsteiner) antibodies in paroxysmal cold hemoglobinuria (PCH). In adults, cold AIHA commonly reflects CAD, a clonal, chronic B-cell lymphoproliferative disorder; secondary CAS occurs with infections or other diseases (eg, autoimmune disorders).2,3 Adult PCH is rare and may be acute or relapsing, with historic associations with syphilis and occasional links to malignancy being reported, although uncommon.4,5 In contrast, pediatric cold AIHA (CAS or PCH) is most commonly seen following viral infections (eg, respiratory or gastrointestinal) and is often transient, and supportive care usually suffices.4, 5, 6, 7 Failing to understand these distinctions poses a risk of inappropriate administration of adult treatment regimens (eg, rituximab or complement-directed therapies) to children who may otherwise recover with supportive care alone.2,3
The investigators used the OBS’CEREVANCE cohort, a national French registry of pediatric patients with AIHA. The registry, which contains data from all pediatric hematology centers in France, spans 32 years and encompassed 658 patients at the time of the authors’ writing. The authors evaluated 142 children (21.6%) with isolated C3d-positive disease, confirming that most cases (63%; 90/142) developed after an infection.
The affected children were young (median age at diagnosis was 3.2 years) and had recent respiratory or gastrointestinal symptoms, and the cases clustered during winter months when viral outbreaks predominated. The seasonal incidence, coupled with favorable outcomes, suggests that most cases of isolated C3d-positive AIHA in children represent a self-limiting immune response to childhood infections rather than a chronic autoimmune process in need of sustained immunosuppression.
Despite a generally favorable prognosis, more than half of the patients presented with severe anemia (median hemoglobin was 6.4 g/dL), and 90% required transfusion support, highlighting the acuity and severity of these seemingly benign conditions. An inadequate reticulocyte response was frequently observed, likely reflecting the abrupt onset of hemolysis.
Corticosteroids were administered to 82% of patients in this cohort despite a lack of evidence to support their use. Steroid-treated patients exhibited more severe anemia at presentation (median hemoglobin 6.3 g/dL vs 7.5 g/dL in children who did not receive steroids), which may explain their significantly longer hospitalization and trend toward a greater number of transfusions. The current recommendations for children with cold AIHA (CAS or PCH) emphasize supportive care (eg, warming measures, folate supplementation, and transfusion via blood warming devices) while awaiting spontaneous resolution.6,8 A systematic review of 230 cases of PCH reported no significant difference in the length of hospitalization between patients who did and those who did not receive corticosteroids.5 Therefore, the available data do not support the efficacy of steroids in pediatric isolated C3d-positive AIHA (CAS or PCH).
If steroids are considered, their use should be individualized. For severe intravascular hemolysis that is refractory to supportive care, complement inhibition (eg, eculizumab, pegcetacoplan, and sutimlimab) may be considered.5
Although most patients in the current study followed a benign course, the 20 patients with immunopathologic manifestations (eg, autoimmune/autoinflammatory conditions, primary immunodeficiencies, and abnormal immune laboratory findings) or relapsing disease afforded valuable insights for patient risk stratification. Patients with immunopathologic manifestations were significantly more likely to have first-degree relatives with immune disorders (45% vs only 6.6% of patients with typical presentations). This suggests that a focused family history of autoimmune disorders or immune deficiencies should be part of the initial evaluation because it may help to identify patients who warrant closer monitoring or additional immunologic assessment.
Relapses were notably rare, observed in only 8 patients, with a cumulative incidence of ∼5% at 2 years. Nonetheless, these cases also offer important insights. Two of the 8 patients had known autoimmune lymphoproliferative syndrome (ALPS); the remaining 6 had no immunopathologic manifestations at diagnosis, and 4 of them exhibited new immune findings (eg, antinuclear antibody positivity and hypogammaglobulinemia) at the time of relapse.
In addition, 5 patients received a diagnosis of primary immunodeficiency, with 4 of those diagnosed with ALPS and 1 with adenosine deaminase deficiency. The collective findings suggest that relapse may unmask underlying immune dysfunction that may not be apparent during the initial presentation; atypical cases should be investigated accordingly.
The study’s limitations were acknowledged appropriately. As a retrospective observational analysis of data that were compiled from 30 institutions, specialized immunohematologic testing was inconsistent. Cold agglutinin testing with thermal amplitude determination and Donath-Landsteiner assessment were rarely performed despite their potential to distinguish between CAS and PCH.9,10 The relatively short median follow-up of 2.8 years also limits the assessment of long-term outcomes, such as underlying immune dysregulation that may manifest over time.
Furthermore, the low frequency of underlying immune disorders in this cohort may not extend to other types of AIHA in the pediatric population (ie, warm or mixed AIHA). As an example, pediatric Evans syndrome (ie, AIHA with immune thrombocytopenia) is associated with immune manifestations and primary immunodeficiencies.11,12
This study, which is the largest systematic analysis of pediatric isolated C3d-positive AIHA cases to date, offers valuable guidance for clinical practice and provides reassurance about the generally favorable outcomes in this population. Most children will recover with supportive care alone, highlighting the self-limiting nature of this condition and suggesting that the routine administration of corticosteroids may be unnecessary and potentially harmful. Initial evaluation should include a focused family history of immune disorders for all patients.
For patients with a positive family history of immune disorders, additional immunologic assessment (eg, immunoglobulin levels and lymphocyte subset analysis) should be considered. Comprehensive immunologic evaluation, including genetic testing, becomes important in the setting of relapse or atypical manifestations (eg, refractory or prolonged hemolysis). Future research should focus on validating clinical prediction tools to identify high-risk patients and refine the diagnostic utility of specialized immunohematologic testing.
Disclaimer: Any views or opinions that are expressed in this manuscript are those of the author’s based on his own scientific expertise and professional judgment; they do not necessarily represent the views of either the Blood Products Advisory Committee or the formal position of the US Food and Drug Administration and do not bind or otherwise obligate or commit either advisory committee or the agency to the views expressed.
Conflict-of-interest disclosure: E.M.B. reports receiving personal fees and nonfinancial support from Grifols, Abbott Laboratories, and UpToDate; and is a member of the US Food and Drug Administration Blood Products Advisory Committee. J.W.J. declares no competing financial interests.